

Bradley J Monk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/949907/publications.pdf>

Version: 2024-02-01

81
papers

5,318
citations

186265

28
h-index

88630

70
g-index

83
all docs

83
docs citations

83
times ranked

5451
citing authors

#	ARTICLE	IF	CITATIONS
1	Testing for High-Risk Human Papillomavirus in Lower Genital Tract Tumors: If Knowledge Does Not Translate to an Action That Helps Patientsâ€™ Why Do It?. Journal of Clinical Oncology, 2022, , JCO2200251.	1.6	0
2	Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. Cancer Treatment Reviews, 2022, 106, 102385.	7.7	44
3	Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecologic Oncology, 2022, 166, 36-43.	1.4	18
4	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENAâ€™MONO/GOG-3020/ENGOT-ov45). Journal of Clinical Oncology, 2022, 40, 3952-3964.	1.6	125
5	ATHENAâ€™MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.. Journal of Clinical Oncology, 2022, 40, LBA5500-LBA5500.	1.6	4
6	Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).. Journal of Clinical Oncology, 2022, 40, 5531-5531.	1.6	0
7	ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigatorâ€™s choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.. Journal of Clinical Oncology, 2022, 40, TPS5620-TPS5620.	1.6	2
8	Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.. Journal of Clinical Oncology, 2022, 40, 5511-5511.	1.6	6
9	Niraparib treatment for patients with <i>BRCA</i>-mutated ovarian cancer: review of clinical data and therapeutic context. Future Oncology, 2022, 18, 2505-2536.	2.4	4
10	Longitudinal Changes in Sleep: Associations with Shifts in Circulating Cytokines and Emotional Distress in a Cancer Survivor Population. International Journal of Behavioral Medicine, 2021, 28, 140-150.	1.7	8
11	Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 2021, 113, 1369-1378.	6.3	8
12	Sequential Chemotherapy for Early-Stage, Postâ€™Radical Hysterectomy Cervical Cancer. JAMA Oncology, 2021, 7, 353.	7.1	1
13	Utilizing an interim fertility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecologic Oncology, 2021, 161, 496-501.	1.4	7
14	Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.. Journal of Clinical Oncology, 2021, 39, 5566-5566.	1.6	0
15	Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).. Journal of Clinical Oncology, 2021, 39, 5519-5519.	1.6	8
16	ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).. Journal of Clinical Oncology, 2021, 39, TPS5603-TPS5603.	1.6	4
17	Efficacy and safety of tisetumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, The, 2021, 22, 609-619.	10.7	186
18	Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902,) Tj ETQq0 0 0r.gBT /Overlock 10 TF		

#	ARTICLE	IF	CITATIONS
19	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. Journal of Clinical Oncology, 2021, 39, TPS5610-TPS5610.	1.6	6
20	Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2021, 39, TPS5607-TPS5607.	1.6	5
21	Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials.. Journal of Clinical Oncology, 2021, 39, 5518-5518.	1.6	2
22	Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis. Gynecologic Oncology, 2021, 161, 422-428.	1.4	8
23	Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).. Journal of Clinical Oncology, 2021, 39, TPS5599-TPS5599.	1.6	1
24	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Medicine, 2021, 10, 3565-3574.	2.8	6
25	Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay. Gynecologic Oncology, 2021, 161, 832-837.	1.4	4
26	The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. Gynecologic Oncology, 2021, 162, 203-209.	1.4	4
27	Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 1034-1046.	10.7	171
28	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. Journal of Clinical Oncology, 2021, 39, 3623-3632.	1.6	69
29	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecologic Oncology, 2021, 163, 274-280.	1.4	59
30	Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 254-261.	1.4	14
31	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENAâ€“MONO) and rucaparib in combination with nivolumab (ATHENAâ€“COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 1589-1594.	2.5	40
32	Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1275-1289.	10.7	118
33	Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2021, , .	1.4	1
34	Reply to Farolfi et al and Haines et al. Journal of Clinical Oncology, 2020, 38, 173-174.	1.6	0
35	Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecologic Oncology, 2020, 156, 100-106.	1.4	14
36	Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer. Gynecologic Oncology, 2020, 159, 581-587.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance. <i>Gynecologic Oncology</i> , 2020, 159, 604-606.	1.4	3
38	Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.	1.4	35
39	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. <i>Gynecologic Oncology</i> , 2020, 159, 150-156.	1.4	43
40	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 159, 79-87.	1.4	6
41	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762.	1.6	82
42	Philip John DiSaia, MD: Available Light & The Origin of Storms. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 959-988.	1.3	0
43	A phase I combination study of vigir and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3002-3002.	1.6	9
44	Randomized double-blind placebo-controlled trial of primary maintenance vigir immunotherapy (VITAL) Tj ETQq0 0 0 rgBT /Overlock 10 T Clinical <i>Oncology</i> , 2020, 38, 6017-6017.	1.6	4
45	Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6050-6050.	1.6	20
46	Niraparib exposure-response relationship in patients (pts) with newly diagnosed advanced ovarian cancer (AOC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6051-6051.	1.6	2
47	Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11547-11547.	1.6	0
48	Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6097-TPS6097.	1.6	1
49	PARP inhibition as frontline therapy in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18, 550-556.	0.3	2
50	PARP inhibition in recurrent ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18, 647-655.	0.3	1
51	Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100506.	0.6	1
52	A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. <i>JAMIA Open</i> , 2019, 2, 505-515.	2.0	56
53	Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2317-2328.	1.6	289
54	Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2968-2973.	1.6	121

#	ARTICLE	IF	CITATIONS
55	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 636-648.	10.7	366
56	Response to surgical management of cervical cancer by laparoscopy or laparotomy. <i>Gynecologic Oncology Reports</i> , 2019, 27, 6-7.	0.6	1
57	The role of proinflammatory immune (IFN-gamma) gene signature in predicting prognosis and response to chemotherapy in uterine carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14209-e14209.	1.6	2
58	CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5597-TPS5597.	1.6	10
59	The role of different TGF β 2 signatures in predicting outcome in high grade serous ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14262-e14262.	1.6	1
60	A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2018, 151, 422-427.	1.4	49
61	The American Society of Clinical Oncology 2018 annual meeting: A review and summary of selected abstracts. <i>Gynecologic Oncology</i> , 2018, 151, e1-e6.	1.4	2
62	Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. <i>Gynecologic Oncology</i> , 2018, 150, 391-397.	1.4	39
63	A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). <i>Gynecologic Oncology</i> , 2018, 150, 247-252.	1.4	56
64	Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2017, 146, 11-15.	1.4	2
65	Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 9.	3.6	30
66	Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 7.	3.6	3
67	A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 146, 554-559.	1.4	15
68	Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). <i>Lancet</i> , The, 2017, 390, 1654-1663.	13.7	424
69	Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 10.	3.6	37
70	A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5526-5526.	1.6	26
71	The role of immune checkpoint inhibition in the treatment of ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 11.	3.6	118
72	The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. <i>Gynecologic Oncology</i> , 2016, 143, 490-495.	1.4	16

#	ARTICLE	IF	CITATIONS
73	Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). <i>Rare Diseases (Austin, Tex)</i> , 2014, 2, e967148.	1.8	40
74	Updates on drug discovery in ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2014, 1, 3.	3.6	3
75	A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. <i>Gynecologic Oncology</i> , 2014, 132, 517-525.	1.4	22
76	Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2014, 133, 439-445.	1.4	35
77	Impact of facility volume on therapy and survival for locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2014, 132, 416-422.	1.4	65
78	Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. <i>Gynecologic Oncology</i> , 2014, 132, 8-17.	1.4	65
79	Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2013, 128, 573-578.	1.4	69
80	Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2473-2483.	27.0	2,011
81	Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5605-5612.	1.6	109